Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

9 Pages (Click to Jump) V  < 1 2 3 4 5 6 7 > »    
 
  
Reply to this topic

RMD, RESMED INC
dan.heath
post Posted: Oct 28 2008, 11:55 AM
  Quote Post


Posts: 685
Thanks: 5


RESMED TO WEBCAST FIRST QUARTER 2009
EARNINGS CONFERENCE CALL
Sydney, Australia, October 24, 2008 -- RESMED INC. (ASX: RMD), announced today that on Friday, November 7, 2008, it will release its earnings for the first quarter of fiscal year 2009, ended September 30, 2008. ResMed will issue an earnings press release after 8:00 a.m. Australian Eastern Daylight Time (AEDT) and will host a conference call to review its quarterly results, market trends, and future outlook.
The conference call is scheduled to begin at 8:30 a.m. Australian Eastern Daylight Time (AEDT) and will be webcast on ResMed's website at www.resmed.com. The online archive of the broadcast will be available approximately 30 minutes after the live call and will continue to be available for two weeks.
International conference call times will be:
9:30 p.m. London (November 6, 2008)
1:30 p.m. San Diego, CA (November 6, 2008)
TO PARTICIPATE in the conference call, please call the below number at least 10 minutes before the call begins and identify yourself to the operator:
International: +1 (617) 614-3673
Conference Name: ResMed Inc. 1Q 2009 Earnings Call
Participant Passcode: 49480223
The replay of the conference call will be available approximately 30 minutes after the call and will be accessible for two weeks at:
International: +1 (617) 801-6888
Passcode: 99471059
ResMed is a leading manufacturer of medical equipment for the treatment and management of sleep-disordered breathing and other respiratory disorders. Further information can be obtained by contacting Matthew Borer at ResMed Inc. at +1 (858) 746-2280; Brett Sandercock at ResMed Limited at (02) 8884-2090, or by visiting the Company’s Web site at www.resmed.com.
- End -

 
dan.heath
post Posted: Aug 6 2008, 11:30 AM
  Quote Post


Posts: 685
Thanks: 5


Good pick up this morning 50 cents up. Might be in for a sustained run with aussie $ likely to head down against the US $ , as interest rates fall. Management is predicting solid growth in 09.
QUOTE
RESMED INC. ANNOUNCES RECORD FINANCIAL RESULTS FOR THE
QUARTER AND YEAR ENDED JUNE 30, 2008
SYDNEY, Australia, August 6, 2008 - ResMed Inc. (ASX: RMD) today announced revenue and income results for the quarter ended June 30, 2008. Revenue for the quarter was a record US$235.2 million, a 23% increase over the quarter ended June 30, 2007. For the current quarter, income from operations and net income were US$37.0 million and US$29.6 million, respectively. Diluted earnings per share for the quarter ended June 30, 2008 was US$0.38. For the quarter ended June 30, 2008, an additional expense of US$3.1 million has been recognized as a charge to cost of sales in relation to the voluntary recall we announced in April 2007 related to our previous series of S8 flow generators. We do not expect any further significant costs in relation to this recall. Excluding product recall expenses, diluted earnings per share was US$0.40, an increase of 14% compared to the quarter ended June 30, 2007. Excluding product recall expenses, gross margin was 58.3%, mainly as the result of encouraging growth in the U.S. market.
SG&A costs were US$77.4 million for the quarter, an increase of US$12.2 million, or 19%, over the same period in fiscal 2007. SG&A costs were 33% of revenue in the June quarter, compared to 34% in the same period in fiscal 2007. The increase in SG&A was primarily due to the addition of selling and administration personnel and related expenses to support sales growth. The increase in SG&A was also due to the net appreciation of international currencies against the U.S. dollar.
R&D expenses during the quarter were US$17.6 million or approximately 7% of revenue. R&D expenses increased 24% year over year. The increase in research and development outlays reflects the continuing commitment to innovation within our product portfolio, as well as an ongoing commitment to clinical research and product development. The increase in R&D was also due to the net appreciation of international currencies against the U.S. dollar.
Amortization of acquired intangibles of US$2.1 million, incurred during the quarter ended June 30, 2008, consisted of amortization of acquired intangible assets associated with our acquisitions of Resprecare, Hoefner, Saime, PulmoMed and PolarMed. Stock-based compensation costs incurred during the quarter ended June 30, 2008, of US$5.3 million, consisted of expenses associated with stock options granted to employees and the employee stock purchase plan.
For the year ended June 30, 2008, revenue was a record US$835.4 million, an increase of 17% over the US$716.3 million for the year ended June 30, 2007. For the year ended June 30, 2008, income from operations and net income were US$143.0 million and US$110.3 million, respectively. GAAP diluted earnings per share for the year ended June 30, 2008 was US$1.40 per diluted share.
Inventory was US$158.3 million as of June 30, 2008, a decrease of US$11.2 million compared to the March 31, 2008 level of US$169.5 million. Accounts receivable days sales outstanding, at 72 days, decreased one day when compared to 73 days for the March 31, 2008 quarter.
Kieran T. Gallahue, Chief Executive Officer, commented, "In the fourth quarter of fiscal 2008, overall sales outside of the Americas totaled US$123.0 million, a 32% increase over the prior year quarter. Americas’ sales were US$112.2 million, an increase of 14% over the prior year quarter. Operating cash flow for the June quarter was a record US$56.8 million and we repurchased US$51.7 million in stock which puts our fiscal year total at US$99.5 million representing 2.6 million shares.”
Mr. Gallahue continued, “We were pleased with the strong and balanced growth achieved by our global operations this past quarter, particularly the accelerated growth experienced in the US market. We are encouraged by the traction gained from our recent product releases: the S8 II series of flow generators and the Swift LT nasal pillows mask.
“Our industry received positive signals that it is poised for continued growth. Home sleep testing took another step forward as both national and local Medicare rulings were released and private insurers, such as the country’s largest insurer, Anthem, issued updated coverage policies. Medicare competitive bidding
implementation was delayed 18-24 months, a positive signal for the home medical equipment industry. Lastly, the International Diabetes Federation published an important consensus statement on sleep apnea and diabetes. The diabetes community now has an official recommendation to screen all type 2 diabetes patients suspected of sleep apnea. ResMed is well positioned to deliver strong growth in fiscal year 2009.”
About ResMed
ResMed is a leading manufacturer of medical equipment for the treatment and management of sleep-disordered breathing and other respiratory disorders. We are dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals for the potentially serious health consequences of untreated sleep-disordered breathing. For more information on ResMed, visit www.resmed.com.
ResMed will host a conference call at 6:30 a.m. Australian Eastern Standard Time (AEST) today to discuss these quarterly results. Individuals wishing to access the conference call may do so via ResMed's web site at www.resmed.com or by dialing +1 (617) 213-8898 and entering conference I.D. No. 31223107. Please allow extra time prior to the call to visit the web site and download the streaming media player (Windows Media Player) required to listen to the Internet broadcast. The online archive of the broadcast will be available approximately 90 minutes after the live call and will be available for two weeks. A telephone replay of the conference call is available by dialing +1 (617) 801-6888 and entering conference I.D. No. 24669616.
Further information can be obtained by contacting Matthew Borer at ResMed Inc., San Diego, at +1 (858) 746-2280; Brett Sandercock at ResMed Limited, Sydney, on +61 (2) 8884-2090; or by visiting the Company's multilingual web site at www.resmed.com.
Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities Litigation Reform Act of 1995. These forward-looking statements, including statements regarding the Company's future revenue, earnings or expenses, new product development, new markets for the Company's products and the impact of future developments related to the recently announced product recall, are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. The Company cannot be certain that it has accurately predicted the costs of the product recall, which could change in response to additional feedback from ongoing discussions with the FDA and with various foreign regulatory bodies. In addition, the product recall could affect the Company’s reputation. Additional risks and uncertainties are discussed in the Company's Annual Report on Form 10-K for its most recent fiscal year and in other reports the Company files with the U.S. Securities & Exchange Commission. Those reports are available on the Company's web site.
- More -
Now 62 cents up.

 
dan.heath
post Posted: Jul 1 2008, 11:48 AM
  Quote Post


Posts: 685
Thanks: 5


In reply to: drrc on Monday 30/06/08 08:23pm

Good pick up there drrc, SP up forty cents this morning, some are taking the article/ rumour seriously.

 
drrc
post Posted: Jun 30 2008, 08:23 PM
  Quote Post


Posts: 2,469
Thanks: 289


Linde eyes ResMed

* Michael West
* June 30, 2008 - 7:34PM


Could it be that another great Australian technology company is about to vanish offshore? Sleep disorder company ResMed is being stalked by German industrial and medical gases giant, the Linde Group.

While Linde, which boasts an enterprise value of 21 billion euro ($34 billion), is close to its trading highs, ResMed is trading not too shy of its lows for the year.

Even at a 50% premium to its prevailing stock price, a takeover bid for ResMed would likely be viewed as opportunistic. Even if it were an agreed cash bid, which is the speculation.

This is a company with minimal debt that dominates a global niche market growing at 20% a year.

Along with Cochlear and CSL, ResMed rounds off the troika of Australian biotechnology stocks that have made it big on the world stage.

However, its shares have been wallowing in the wake of a weak US dollar and discounting by archrival Respironics.

Respironics was recently acquired by Royal Philips.

ResMed and Respironics control roughly 40% of the market for CPAP devices portable machines which combat sleep apnea. Fisher & Paykel is the third player with about 7%.

Sleep apnea is responsible for around half of all sleep disorders. As more causal links emerge between various sleep disorders and the likes of heart failure, stroke and the onset of diabetes, demand for medical devices has increased. They work.

ResMed's growth, however, has been constrained by the predominance of its machines in US hospitals. The US is Resmed's largest market and health-care costs there are prohibitive.

As it ramps up sales of portable devices however, its profit margins are expected to improve.

Strategically, a takeover of ResMed makes perfect sense for Linde, which recently took over industrial gases group BOC and already has distribution channels into health care and hospital markets.

Locally, BOC Australia was sold not to Linde, but to Wesfarmers.

Though Wesfarmers has its enormous acquisition of Coles to digest, ResMed would make an appetising deal indeed as the WA conglomerate already has distribution in medial gases.

http://business.theage.com.au/linde-eyes-r...80630-2zdo.html

 
donnaleighh
post Posted: Feb 21 2008, 04:14 PM
  Quote Post


Posts: 336
Thanks: 12


In reply to: Spicer69 on Friday 02/11/07 04:44pm

Hey Spicer... you getting the sense that the RMD play is near again? Seems the pattern is coming into play again - although I would like to see the DMI close out a bit more - watching closely now - but sensing it may be close to a buy in with tight stops esp. in current times - interested your thoughts as you seem to pick this play very sweetly indeed. Cheers, Donna

 
Spicer69
post Posted: Dec 26 2007, 09:36 AM
  Quote Post


Posts: 324
Thanks: 1


Sill holding.....I love it when a plan comes together......Merry Xmas...... hypocrite.gif

 

sentifi.com

Share Cafe Sentifi Top themes and market attention on:


Spicer69
post Posted: Nov 15 2007, 03:24 PM
  Quote Post


Posts: 324
Thanks: 1


A litle bit of a breather with some profit taking...I hope you're right BSA $5.30 and up and away....I should trust my gut feel more often and bailed above $5.10 for a re-entry this morning.

 
donnaleighh
post Posted: Nov 15 2007, 11:41 AM
  Quote Post


Posts: 336
Thanks: 12


In reply to: Spicer69 on Tuesday 13/11/07 06:33pm

Spicer, cheers, no offense taken (takes a lot to get my back up) and often fine for a rant and rave myself...will continue to keep an eye here but for the present I'm out - too many fingers in other pies - SLA - yeah - haven't taken the leap yet but much lower and I won't be able to help myself... keep me posted when you spot the next RMD trade - its was a gem... Cheers D

 
BSA
post Posted: Nov 14 2007, 10:11 AM
  Quote Post


Posts: 8,001
Thanks: 403


In reply to: Spicer69 on Tuesday 13/11/07 05:33pm

Hi Spicy, RMD not one of my better traders as I seem to go out on stop a bit (BSA not in synch) and had taken it off my list of tradables.

You have called it well cool.gif The recent action has price action back above previous support around $4.95, be nice to see it hold above this level on a closing basis. A wee bit of consolidation around current levels to soak up some sellers from this previous consolidation zone(blue elliptical zone) and traders taking profits from recent run and it may have a go at the more significant $5.30 level,...perhaps?

Cheers
Attached image(s)
Attached Image

 




--------------------


 
Spicer69
post Posted: Nov 13 2007, 06:33 PM
  Quote Post


Posts: 324
Thanks: 1


QUOTE (donnaleighh @ Tuesday 13/11/07 08:45am)


Ok donnaleighh, now we have to question todays trading...plenty of support but when it hit it's high today I very nearly bailed the lot for a DAY TRADE...ie the high had some pro trading in it....but it stopped......small pro traders (like me)bailed.....now I suspect it'll be the big pro's tomorrow.
Taking profit at the high would have been worth it, I saw it coming, and take the $4.03 re-entry since .035% is my cost of a trade in and out scenario.... would have bought back in but got waylayed by a mate with a few beers so missed it....Whaaaa!

Not!....hehe.....I am hoping tomorrow will yeild a similar rise, but it may take a while to see the money roll in after, so will keep a good eye on it.....anyway todays trading was great, but I hate to see downward skyrockets (like todays candlestick, even if they are in the up side)....dunno how much you know about trading but here's a good site for you anyway..... http://www.investopedia.com/terms/r/rocketscientist.asp .....I Recon you trade: take no offense putting you onto that site....

I followed my rules so far, within reason----there's always the exception though....and am in a very nice profit ATM....10% average profit in 10 days on a CFD trade with a 10% margin is 100% profit. ....the biggest casino in the world!

look for this 4 drop pattern IMO....if it flattens at the bottom it's probably a good one.....tight stops my friend....and DYOR

Burp..... Still having a few coldies.....as we do .....

PS if you want to play a realy wierd one, check SLA with some of your profits....Im banking on it long term....ie totaly retiring.....Pipe dreams but so far so good ,and one announcement by an independant put it as a good speccy buy....Burp!....just have a sqizz and dyor and make up your own mind!

ph34r.gif ....DYOR.,.....BALH BLAH....sorry I rant a bit...hehe

 
 


9 Pages (Click to Jump) V  < 1 2 3 4 5 6 7 > » 

Back To Top Of Page
Reply to this topic


You agree through the use of ShareCafe, that you understand and accept the TERMS OF USE.


TERMS OF USE  -  CONTACT ADMIN  -  ADVERTISING